A Phase 3 interventional study of BMS-986278 in Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb. Not yet recruiting at 275 sites in 27 countries. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Pulmonary Fibrosis with a site in China — 14 open to participants now, 18 under way, 4 of them phase 3. Pulmonary Fibrosis · China.
Among the 40 studies in Pulmonary Fibrosis with a site in China, this one has the largest planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 3, reaches primary completion later than 17 of the 17 other live ones, and was the 37th registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →14 of the 40 studies in Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–85 · Healthy volunteers
Ming Zhong · Sites in China
Ages 18–89
Zuojun Xu · Sites in China
ChromX Health · Sites in China
Ages 18–100 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 10 · Phase 3 8
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,380 is above the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.
Median enrollment 146 across the 30 interventional studies, 200 across the 10 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 40 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 9 studies filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Fibrosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125327Phase 3Guangzhou JOYO Pharma Co., LtdSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | 2026-12-31 |
| NCT05139719Sunshine Lake Pharma Co., Ltd.A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients | 2026-12 |
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT07396467The First Affiliated Hospital with Nanjing Medical UniversityClinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis | 2026-12-31 |
| NCT07464132Peking Union Medical College HospitalApplication of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases | 2027-02-17 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Pulmonary Fibrosis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of in either IM027068 or IM0271015.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986278
Specified dose on specified days
Also known as: Admilparant
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to Week 100
Number of Participants With Serious Adverse Events (SAEs)
Time frame: Up to Week 100
Number of Participants With AEs leading to Discontinuation
Time frame: Up to Week 100
Number of Participants With AEs leading to Deaths
Time frame: Up to Week 100
Number of Participants With Clinically Significant Laboraty Abnormalities
Time frame: Up to Week 100
Number of Participants With Clinically Significant Electocardiogram (ECG) Abnormalities
Time frame: Up to Week 100
Number of Participants With Clinically Significant Vital Sign Abnormalities
Time frame: Up to Week 100
Showing the first 100 of 275 sites across 27 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Start is estimated for Dec 2026; primary completion for Nov 2029, 35 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Admilparant